If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  Initiating Twice-Daily Rather Than Once-Daily Biphasic Insulin Aspart Improves Glycaemic Control: Reported at EASD By Bruce Sylvester VIENNA, Austria -- October 7, 2009 -- While biphasic insulin aspart 30/70 (BIAsp 30) is an effective treatment for patients with type 2 diabetes, regardless of initial or final injection regimen, initiating BIAsp 30 therapy with twice-daily (BID) injections more effectively improves glycaemic control than initiating treatment with a once-daily (OD) injection regimen. Researchers reported the findings here October 2 in an oral session at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD). “We saw significant reduction in Hb [haemoglobin] A1C, fasting plasma glucose, and postprandial glucose across all treatment groups,” said presenter and lead investigator Robert Ligthelm, MD, EHM Clinic, Hoofddorp, the Netherlands. “Initial twice-daily regimen resulted in better glycaemic control than initial once-daily injection.” Data from the Observational Study of Safety and Effectiveness of NovoMix 30 for the Treatment of Diabetes Mellitus (IMPROVE) showed that BIAsp 30 improves glycaemic control in type 2 diabetes patients without regard to pre-study therapy. The present subanalysis was done to determine the effectiveness and safety of BIAsp 30 in patients grouped according to their starting and final injection frequency, in order to determine which regimens produce best outcomes. Of the 52,419 patients in IMPROVE, 41,436 were included in the analysis, since they had available injection frequency data for baseline visit and final visit. Researchers divided the patients into 5 treatment regimens based on their starting and final injection frequency of BIAsp 30: OD (n = 2,943); OD to BID (n = 2,613); BID (n = 33,880); OD to 3 times-daily (TID; n = 141); and BID to TID (n = 1,859). Patients in all dosing groups achieved statistically significant reductions from baseline in Hb A1C, fasting blood glucose, and postprandial blood glucose by the end of the study (all P < .0001). Patients initiating treatment with BID injections achieved consistently greater reductions in glycaemic parameters than patients who started with an OD injection. Over 50% of patients initiating treatment with BID injections achieved Hb A1C <7.0%, compared with approximately 40% of OD patients. Final injection frequency did not appear to influence glycaemic outcome. All groups showed a significant reduction (P < .0001 for all groups) in major hypoglycaemic events. Minor hypoglycaemia decreased significantly in those who finished on OD or BID and increased in patients who finished on TID. Thus, initial BID regimen resulted in better glycaemic control than initial OD injection, and overall, BIAsp 30 is an effective therapy regardless of initial or final injection regimen. Funding for this study was provided by Novo Nordisk A/S. [Presentation title: Examining Patient Outcomes Following Different Regimens of Biphasic Insulin Aspart 30/70 (BIAsp 30, NovoMix 30) in the Large, Multinational, IMPROVE Observational Study. Abstract 214]
|
